Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Re: Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the reduction by dutasteride of prostate cancer events trial.
Oelke M.
Eur Urol. 2012 Mar;61(3):624-5. No abstract available.
Related citations
Re: A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.
Moyad MA.
Eur Urol. 2012 Mar;61(3):623-4. No abstract available.
Re: Prediction of erectile function following treatment for prostate cancer.
Schellhammer P.
Eur Urol. 2012 Mar;61(3):622. No abstract available.
Re: Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection.
Delongchamps NB, Zerbib M.
Eur Urol. 2012 Mar;61(3):622-3. No abstract available.
Words of wisdom. Re: Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
Schmid HP, Theiler R.
Eur Urol. 2012 Feb;61(2):427-8. No abstract available.
Words of wisdom. Re: Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force.
Schröder FH.
Eur Urol. 2012 Feb;61(2):423-4. No abstract available.
Comment on the US Preventive Services Task Force's draft recommendation on screening for prostate cancer.
Kwiatkowski M, Klotz L, Hugosson J, Recker F.
Eur Urol. 2012 Apr;61(4):851-4. Epub 2012 Jan 24. No abstract available.
Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature.
Chade DC, Eastham J, Graefen M, Hu JC, Karnes RJ, Klotz L, Montorsi F, van Poppel H, Scardino PT, Shariat SF.
Eur Urol. 2012 May;61(5):961-71. Epub 2012 Jan 23.
The impact of interscreening interval and age on prostate cancer screening with prostate-specific antigen.
Wu GH, Auvinen A, Yen AM, Hakama M, Tammela TL, Stenman UH, Kujala P, Ruutu M, Chen HH.
Eur Urol. 2012 May;61(5):1011-8. Epub 2012 Jan 14.
Personalized treatment of prostate cancer based on inherited variations of steroid pathway-related genes.
Todenhöfer T, Schwentner C, Stenzl A.
Eur Urol. 2012 Jul;62(1):97-9. Epub 2012 Jan 3. No abstract available.
Re: office based transrectal saturation biopsy improves prostate cancer detection compared to extended biopsy in the repeat biopsy population.
Patel A.
Eur Urol. 2012 Jan;61(1):223-4. No abstract available.
Nodal staging in prostate cancer: still an unresolved issue.
Joniau S, Van den Bergh L, Peeters C, Haustermans K, Spahn M.
Eur Urol. 2012 Jun;61(6):1139-41. Epub 2011 Dec 28. No abstract available.
Error occurred: cannot get document summary
Novel molecular targets for the therapy of castration-resistant prostate cancer.
Agarwal N, Sonpavde G, Sternberg CN.
Eur Urol. 2012 May;61(5):950-60. Epub 2011 Dec 22.
The impact of germline genetic variations in hydroxysteroid (17-Beta) dehydrogenases on prostate cancer outcomes after prostatectomy.
Audet-Walsh E, Bellemare J, Lacombe L, Fradet Y, Fradet V, Douville P, Guillemette C, Lévesque E.
Eur Urol. 2012 Jul;62(1):88-96. Epub 2011 Dec 21.
The benefits of risk assessment tools for prostate cancer.
Thompson IM, Ankerst DP.
Eur Urol. 2012 Apr;61(4):662-3. Epub 2011 Dec 20. No abstract available.
Re: Henk G. van der Poel, Tessa Buckle, Oscar R. Brouwer, Renato A. Valdés Olmos, Fijs W.B. van Leeuwen. Intraoperative laparoscopic fluorescence guidance to the sentinel lymph node in prostate cancer patients: clinical proof of concept of an integrated functional imaging approach using a multimodal tracer. Eur Urol 2011;60:826-33.
Polom K, Murawa D, Polom W.
Eur Urol. 2012 Mar;61(3):e18; author reply e19-20. Epub 2011 Dec 13. No abstract available.
Re: Mieke Van Hemelrijck, Hans Garmo, Lars Holmberg, et al. Multiple events of fractures and cardiovascular and thromboembolic disease following prostate cancer diagnosis: results from the population-based PCBaSe Sweden. Eur Urol 2012;61:690-700.
Cai T, D'Elia C, Detti B.
Eur Urol. 2012 Apr;61(4):e27; author reply e28. Epub 2011 Dec 9. No abstract available.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on